Compare Globus Medical Inc. Class A Common Stock (GMED) vs Remitly Global Inc (RELY) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

RELY trades at $23.49, showing modest daily movement with strong technical momentum. The company demonstrates accelerating revenue growth, reaching $1.64 billion in 2025 with improving profitability margins. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.93 significantly exceeding the $0.12 forecast. Analyst sentiment remains overwhelmingly positive with 92% buy ratings and a $30.50 consensus price target, representing 30% upside potential from current levels.

The outlook remains bullish given strong fundamentals and growth trajectory, though the stock faces risks from competitive pressures and potential market volatility. RELY's transition to profitability and expanding customer base to over 10 million active users supports continued upside, while elevated valuation multiples require sustained execution to justify current levels.